Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Date:5/8/2008

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City. Co- investigators for the study are Eric Feldman, M.D. and Gail Roboz, M.D.

The objectives of the trial are: (i) to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given in combination with cytarabine to AML and high-risk MDS patients over the age of 60, and (ii) to evaluate this combination further for safety and efficacy in a larger cohort of patients. Cloretazine(R) (VNP40101M) will be given as a 30 - 60 minute infusion on day 1 approximately 3-4 hours after the start of the cytarabine infusion. Cytarabine will be administered as a continuous infusion of 100 mg/m2/day for 7 days. In the Phase I portion of the study, dose escalation will be done in cohorts of at least 3 patients and the maximum tolerated dose (MTD) identified in the Phase I segment will be used in the Phase II segment of the study.

Ann Cahill, Vice President, Clinical Development, commented, "It is important for us to continue to study Cloretazine(R) (VNP40101M) in combination with different doses and schedules of cytarabine, the most widely used drug in the treatment of AML. In addition, we want to evaluate Cloretazine(R) (VNP40101M) in a broader group of elderly patients than are currently being studied in our pivotal tri
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Reportlinker.com announces that a new market research ... Levosimendan - Comprehensive patent search ... unnecessary risk with the industry benchmark in comprehensive ... regularly updated, professional patent search performed by our ...
... 20, 2011 Sagent Pharmaceuticals (Nasdaq: SGNT ) ...  The size of the offering has been increased from the ... of common stock at a price to the public of ... on The NASDAQ Global Market on April 20, 2011 under ...
Cached Medicine Technology:Reportlinker Adds Levosimendan - Comprehensive patent search 2Reportlinker Adds Levosimendan - Comprehensive patent search 3Reportlinker Adds Levosimendan - Comprehensive patent search 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 ... "McDonald’s continues to market to a disadvantaged ... Hispanic. They use proven, often offensive, ethnically-slanted ... of people." ('The Tainted Burger." Amazon: ... with Anna Lappe', author and activist who ...
(Date:7/27/2014)... (PRWEB) July 28, 2014 Zensah®, the leader ... offering to include a wrist support . The wrist ... the wrist area. , Lateral and Medial Epicondylitis, more commonly ... condition in which there is inflammation of the tendons attached ... unrelated to wrist pain, the muscles that work the wrist ...
(Date:7/27/2014)... a reliable online supplier of women’s special occasion outfits, has ... on its website. Now, all these charming gowns are provided ... are pleased to add the new fabulous prom dress collection ... who are in need of fashionable special occasion outfits. Each ... our clients will love them. Ladies, just visit our online ...
(Date:7/27/2014)... Bags underneath the eyes is one condition that both ... a range of new products now available from Internet retailers. ... serum review that is now posted for adults to access ... with baggy eyes and how the natural ingredients in some ... also provides a detailed overview of the creams and oils ...
(Date:7/27/2014)... virus (HEV) transmission by blood components indicates that about ... their plasma. The findings, published in The Lancet ... red cells, platelets, and fresh frozen plasma) are likely ... The study retrospectively screened 225 000 individual blood donations ... Sept, 2013 for HEV RNA. 79 donors were found ...
Breaking Medicine News(10 mins):Health News:The Tainted Burger- McDonalds's Franchise Owner's Tale by Author Michael B. Potts Says McDonald's Disproportionately Markets to Minorities--Tedx Video Supports Claim 2Health News:Zensah® Releases New Wrist Support 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... Feb. 3 The Ensign Group, Inc. (Nasdaq: ... into Colorado by acquiring four long-term care facilities in ... a 35-bed skilled nursing facility in Littleton, Arvada Nursing ... Temple Center, a 128-bed skilled nursing facility in Englewood, ...
... DEL MAR, Calif., Feb. 3 Plastic & ... the field, published the remarkable safety record of ... killer blood clots to the lungs (pulmonary embolism ... over the past 16 years! This series included ...
... for online vacuum cleaner reviews. , ... Boise, Idaho (PRWEB) February 3, ... will collaborate with The Carpet and Rug Institute (CRI) to ... "Seal of Approval" designation. , , , , ,The new series seeks ...
... web based user self service & identity management software solution that allows ... accounts easily and securely via a web browser, and ends the need ... ... 3, 2009 -- SysOp Tools, Inc. announced that Password Reset PRO, a ...
... Feb. 3 Beneficiaries enrolled in Medicare Part D ... as the "doughnut hole" were much less likely to ... according to a University of Pittsburgh Graduate School of ... 3 online issue of Health Affairs , raise ...
... in the February issue of the Journal of the ... to 20 minutes with simple surgical exercises prior to an ... skills in surgeons of all experience levels. The researchers found ... surgeons, alertness to a higher level for surgical procedures and ...
Cached Medicine News:Health News:The Ensign Group Expands into Colorado 2Health News:Cosmetic Surgery - No Killer Blood Clots to the Lungs Sans GA, PK Anesthesia Can Save the Day 2Health News:The Housekeeping Channel (HC) and The Carpet and Rug Institute (CRI) Partner on Vacuum Cleaner Reviews 2Health News:The Housekeeping Channel (HC) and The Carpet and Rug Institute (CRI) Partner on Vacuum Cleaner Reviews 3Health News:New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level 2Health News:New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level 3Health News:Seniors in Medicare's doughnut hole decrease use of meds 2Health News:Journal of American College of Surgeons study finds warm-up helps surgeons improve performance 2
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... The Universal Biomedical Amplifier (UBA-4204) ... true DC signal amplification and ... commonly seen amplifier problems of ... saturation. These features make the ...
The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...
... PACHETTE 3 will enable eye care professionals ... utilizing improved ultrasound technology. The PACHETT 3 ... algorithm used in all the DGH pachymeters ... DGH Model 555 PACHETTE 3 is capable ...
Medicine Products: